IFNB1 and myeloid sarcoma: Although more than 10 disease-modifying therapies (IFN-β, glatiramer acetate, mitoxantrone, natalizumab, fingolimod etc.)are now used for MS, they are not fully efficient and patients suffer from many symptoms because of the adverse effects and limitations of causal treatment [31,32].